Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.77 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 12/20 | 0.76 |
| ▸ | HPGD | P15428 | 6/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.76 |
| ▸ | GAA | P10253 | 5/20 | 0.76 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701145 | 1.00 | KDM4E (0.77) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL4428703 | 0.87 | KDM4E (1.00) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL4420851 | 0.79 | ALDH1A1 (0.74) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL4425365 | 0.79 | ALDH1A1 (0.74) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL4417733 | 0.78 | KDM4E (0.82) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL13598876 | 0.78 | KDM4E (0.82) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL4175139 | 0.75 | KMT2A (0.78) | ALDH1A1HSD17B10POLBMAPTMEN1 | |
| SCHEMBL5773842 | 0.75 | KDM4E (0.77) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL4424303 | 0.75 | ALDH1A1 (0.71) | KDM4EALDH1A1TAAR1HSD17B10HPGD | |
| SCHEMBL5646247 | 0.75 | MAPT (0.82) | KDM4EALDH1A1HSD17B10HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | KDM4E 3303/4885ALDH1A1 3104/4885TAAR1 1545/4885 |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | KDM4E 3082/4885ALDH1A1 2364/4885TAAR1 1323/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | KDM4E 3560/4885ALDH1A1 2366/4885TAAR1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.